Citadel Advisors
ABVC icon

Citadel Advisors’s ABVC BioPharma ABVC Stock Holding History

Citadel Advisors’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3K Buy
+11,600
New +$14.4K ﹤0.01% 13420

Other funds holding ABVC

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors's ABVC Position: Q2 2026 in Review

Citadel Advisors opened a new position in ABVC BioPharma (ABVC) in Q2 2026: 72,091 shares worth $114K. The stake represents ﹤0.01% of the portfolio and ranks #12593 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ABVC as recently as Q4 2025.

Citadel Advisors first reported a position in ABVC in Q3 2022 and has held it in 8 quarters since. The position peaked at $118K in Q4 2025. 15 funds tracked by Wall St. Rank hold ABVC as of Q2 2026.

  • Citadel Advisors held 72,091 shares of ABVC BioPharma worth $114K as of Q2 2026.
  • ABVC BioPharma was a new Citadel Advisors position in Q2 2026.
  • ABVC BioPharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12593 holding.
  • Citadel Advisors first reported a position in ABVC BioPharma in Q3 2022 and has held it in 8 quarters since.
  • Citadel Advisors's ABVC BioPharma position peaked at $118K in Q4 2025.
  • 15 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.